Evaluating risk-based allocation strategies for PCSK9 inhibitors: results from a simulation study in a contemporary ASCVD cohort

Back

ESC Professional Premium Access

Evaluating risk-based allocation strategies for PCSK9 inhibitors: results from a simulation study in a contemporary ASCVD cohort

Session: Risk factors and prevention: lipids (2)

Topic: Drug therapy

Speaker: Doctor C. Blaum (Hamburg, DE)

Event: ESC Congress 2023

Congress Presentation

About the speaker

Doctor Christopher Blaum

University Heart and Vascular Centre Hamburg (UHZ), Hamburg (Germany)

1 presentation

0 follower

8 more presentations in this session

Hyperlipoproteinemia(a) in coronary artery disease patients: who are patients with very high levels and how do they respond to the PCSK9 antibody therapy?

Speaker: Doctor M. Novakovic (Ljubljana, SI)

Prevalence and outcomes of familial hypercholesterolemia in young patients undergoing coronary bypass surgery

Speaker: Doctor J. Black (Hobart, AU)

Increased triglyceride independently associates with premature structural and functional cardiac damage progression in asymptomatic adolescents: a 7-year longitudinal study

Speaker: Doctor A. Agbaje (Kuopio, FI)

Characterization of lipidic coronary atheroma under control of low-density lipoprotein <1.8 mmol/l and lipoprotein (a) <50 mg/dl in patients with coronary artery disease

Speaker: Doctor D. Shishikura (Takatsuki, JP)

Increased Lipoprotein (a) and familial hypercholesterolemia: a dangerous combination.Data from a 12-year follow-up study

Speaker: Doctor I. Andrikou (Athens, GR)

Access the full session

Risk factors and prevention: lipids (2)

Speakers: Doctor C. Blaum, Doctor M. Novakovic, Doctor J. Black, Doctor A. Agbaje, Doctor D. Shishikura...

Access

About the event

ESC Congress 2023

25 August - 28 August 2023

Sessions Presentations

Congress

Evaluating risk-based allocation strategies for PCSK9 inhibitors: results from a simulation study in a contemporary ASCVD cohort

About the speaker

Doctor Christopher Blaum

8 more presentations in this session

Hyperlipoproteinemia(a) in coronary artery disease patients: who are patients with very high levels and how do they respond to the PCSK9 antibody therapy?

Prevalence and outcomes of familial hypercholesterolemia in young patients undergoing coronary bypass surgery

Increased triglyceride independently associates with premature structural and functional cardiac damage progression in asymptomatic adolescents: a 7-year longitudinal study

Characterization of lipidic coronary atheroma under control of low-density lipoprotein <1.8 mmol/l and lipoprotein (a) <50 mg/dl in patients with coronary artery disease

Increased Lipoprotein (a) and familial hypercholesterolemia: a dangerous combination.Data from a 12-year follow-up study

Access the full session

Risk factors and prevention: lipids (2)

About the event

ESC Congress 2023

ESC 365 is supported by